Labcorp to Expand Clinical Trial Operations in Brazil with Dedicated Kit Assembly and Future Laboratory Operations through Collaboration with Grupo Fleury

November 17, 2026

Expansion will bring clinical trial services closer to research sites and patients while supporting global studies

BURLINGTON, N.C., Nov. 17, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with Grupo Fleury, one of Brazil's leading healthcare and diagnostic groups, with extensive laboratory infrastructure, scientific expertise and a strong presence across the Brazil healthcare ecosystem, to expand clinical trial operations in the country. Through the collaboration, Labcorp plans to launch local clinical trial kit assembly operations, followed by laboratory operations, helping sponsors conduct studies more efficiently while bringing services closer to research sites and patients across Brazil.

Labcorp's wholly owned central laboratory network spans North America, Europe, Asia and Africa. The collaboration with Grupo Fleury in Brazil expands Labcorp's clinical trial support capabilities across five continents. Brazil is a key destination for clinical research, supported by a diverse patient population and experienced investigators. The Grupo Fleury-supported new operations will provide sponsors with local support while maintaining the quality standards, scientific expertise and data consistency used across Labcorp's global network.

"Clinical trials today often span multiple countries, and sponsors need partners that can combine global expertise with local insight," said Brian Caveney, M.D., president, biopharma laboratory services and chief medical and scientific officer, Labcorp. "Our expansion in Brazil reflects the country's growing role in global clinical research while maintaining the high standards and consistency sponsors expect across global studies."

"Brazil continues to strengthen its position in global clinical research, supported by a diverse patient population, strong scientific capabilities and experienced research teams," said Edgar Rizzatti, president of Grupo Fleury's Medical, Technical, Hospitals, New Links and Innovation Business Unit. "By combining Grupo Fleury's scientific expertise, operational excellence and deep understanding of the local research environment with Labcorp's global clinical trial capabilities, we can help make clinical trials more efficient, broaden access to research opportunities and support the continued development of Brazil's clinical research ecosystem."

Local kit assembly is expected to begin in early 2027, while laboratory operations remain in development and are expected to launch by the end of 2027. Both operations will use Labcorp's global systems, processes and quality standards to support multinational clinical trials.

By establishing operations in Brazil, Labcorp expects to shorten kit delivery times, reduce reliance on international shipping and improve operational efficiency for clinical trial sponsors.

To learn more, visit: https://www.labcorp.com/biopharma/central-labs/locations.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements about the planned expansion of clinical trial operations into Brazil, with local kit assembly anticipated to be established in early 2027 and laboratory operations to follow by the end of 2027, and the expected benefits to clinical trial sponsors from Labcorp's expanded global footprint.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond Labcorp's control. These factors, in some cases, have affected and in the future (together with other factors) could affect Labcorp's ability to implement its business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

Labcorp has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in Labcorp's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in

subsequent quarterly reports on Form 10-Q and its other filings with the SEC. The information in this press release should be read in conjunction with a review of Labcorp's filings with the SEC including the information in its most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".

View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-to-expand-clinical-trial-operations-in-brazil-with-dedicated-kit-assembly-and-future-laboratory-operations-through-collaboration-with-grupo-fleury-302942468.html

SOURCE Labcorp

Media, Alissa Lawver, Media@Labcorp.com; Investors, Nickolo Russo, Investor@Labcorp.com